ArticleThe oncologist2026

Benefit-risk balance of S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).

Jean-Christophe Chiem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.